FDA Adverse Event Injury Summary report: N

RADIESSE DERMAL FILLER

MDR report key: 2084763 · Received April 29, 2011

Report

Report Number
2135225-2011-00025
Event Type
Injury
Date Received
April 29, 2011
Date of Event
March 25, 2011
Report Date
April 4, 2011
Manufacturer
MERZ AESTHETICS, INC. (FORMERLY BIOFORM MEDICAL, INC)
Product Code
LMH
PMA / PMN Number
P050052
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
HI, US
Reporter Occupation
PHYSICIAN

Narratives

Additional Manufacturer Narrative · 1

THE PHYSICIAN PRESCRIBED PREDNISONE, CLEOCIN, CIPRO, CEPHALEXIN, AND APPLIED NITRO PASTE TO THE AFFECTED AREA. THE PT EXPERIENCED VASCULAR COMPROMISE WITH NECROSIS AND TREATMENTS INCLUDING VINEGAR SOAKS AND OCCLUSIVE DRESSINGS WERE ALSO PROVIDED. THE PT RETURNED FOR EVALUATION ONE WEEK LATER WITH TENDERNESS AND REDNESS PERSISTING. SHE DID NOT REPORT THE RESULTS OF HER EYE APPOINTMENT TO THE INJECTING PHYSICIAN. THE RESULTS OF THE ER VISIT HAVE NOT BEEN PROVIDED. DURING LATER F/U, THE PHYSICIAN REPORTED THE PT IS DOING BETTER. SHE HAS SOME SCABBING ON THE RIGHT SIDE OF THE NOSE. THE AREA IS SLIGHTLY RED; HOWEVER, THE SKIN IS BEGINNING TO HEAL. HE IS UNSURE IF THERE WILL BE ANY SCARRING REMAINING. THE OPTION OF A PULSED DYE LASER TREATMENT WAS DISCUSSED WITH THE PT BUT SHE REMAINS UNDECIDED AT THIS TIME. A REVIEW OF THE DEVICE HISTORY RECORDS INDICATES THE REPORTED LOT #1021366 MET ALL SPECIFICATIONS PRIOR TO RELEASE.

Description of Event or Problem · 1

PHYSICIAN REPORTED A PT INJECTED WITH RADIESSE IN THE DORSUM AND TIP OF THE NOSE DEVELOPED PAIN SEVERAL HOURS POST-INJECTION. SHE LATER EXPERIENCED RED STREAKS TRAVELING UP TO THE GLABELLA WITH PUSTULES, BLACKENED SKIN WITH TISSUE SLOUGHING AT RIGHT CHEEK, EYE AREA AND NOSE. SHE ALSO REPORTED SOME VISION IRREGULARITIES. THE PT LATER WENT TO AN EYE DOCTOR AND TO THE ER.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 RADIESSE DERMAL FILLER INJECTABLE IMPLANT LMH MERZ AESTHETICS, INC. (FORMERLY BIOFORM MEDICAL, INC) 1021366

Patients

Seq Age Sex Outcome Treatment
1 UNK Required Intervention